Genetic correlation and causal associations between circulating C-reactive protein levels and lung cancer risk
“Conclusion: There may be a genetic and causal association between circulating CRP levels and the risk of SCLC, which is in line with previous population-based observational studies.”
Ex-YouTube chief Susan Wojcicki dies at 56 of lung cancer
“SAN FRANCISCO: Tech pioneer and former YouTube chief Susan Wojcicki, who played an instrumental role in the rise of Google, has died at the age of 56 after battling lung cancer, her husband announced on Friday.”
Rheumatoid Arthritis Tied to Higher Risk for Lung Cancer
“FRIDAY, Aug. 9, 2024 — Rheumatoid arthritis (RA) is associated with a significantly increased risk for lung cancer, according to a study published online July 28 in Arthritis & Rheumatology. “RA was associated with a >50 percent increased risk of lung cancer, and RA-ILD represented a particularly high-risk group with an approximate threefold increased risk,” the authors write. “Increased lung cancer surveillance in RA, and especially RA-ILD, may be a useful strategy for reducing the burden posed by the leading cause of cancer death.””
AFFINITY Study Completes Enrollment for Novel Aliya PEF System in Advanced Lung Cancer
“Aliya works by delivering high voltage, short duration electrical energy locally, which changes the transmembrane potential of cells and leads to loss of homeostasis. This can induce nonthermal programmed cell death without denaturing cellular proteins or the extracellular matrix. Preclinical and prior clinical feasibility studies of Aliya show the potential of this process in releasing antigens from the dying tumor cells that may stimulate an immune response for a potential systemic effect beyond focal ablation.”
New Study Assesses Ifinatamab Deruxtecan for Treatment of Small Cell Lung Cancer
“Merck has recently announced the initiation of their Ideate-Lung02 (NCT06203210) trial—a global, multicenter, randomized, open-label phase 3 study that assesses the efficacy and safety of ifinatamab deruxtecan (I-DXd; Daiichi Sankyo) to treat individuals with relapsed small cell lung cancer (SCLC).”
A fractional-order model for optimizing combination therapy in heterogeneous lung cancer: integrating immunotherapy and targeted therapy to minimize side effects
“This research presents a novel approach to address the complexities of heterogeneous lung cancer dynamics through the development of a Fractional-Order Model. Focusing on the optimization of combination therapy, the model integrates immunotherapy and targeted therapy with the specific aim of minimizing side effects. Notably, our approach incorporates a clever fusion of Proportional-Integral-Derivative (PID) feedback controls alongside the optimization process.”
Invenio enrolls 1st patients in AI-based lung cancer image analysis study
“Invenio Imaging announced that it has begun enrolling patients in a pivotal study of its artificial intelligence (AI)-based image analysis module for lung cancer. The On-Site study is a multicenter study in bronchoscopy combining stimulated Raman histology with AI for rapid lung cancer detection; it will be conducted at centers that include the University of Texas MD Anderson Cancer Center, Corewell Health, the Memorial Sloan Kettering Cancer Center, and the University of North Carolina (UNC) at Chapel Hill.”
MSD discontinues Phase III KeyVibe-008 trial for lung cancer treatment
“SD (Merck & Co) has discontinued the Phase III KeyVibe-008 trial designed to evaluate a fixed-dose combination of vibostolimab and pembrolizumab with chemotherapy for extensive-stage small cell lung cancer (ES-SCLC). The company’s decision follows a recommendation from an independent Data Monitoring Committee (DMC) after a pre-planned analysis indicated that the trial’s primary endpoint of overall survival (OS) met pre-specified futility criteria.”
LP-300 Shows Promise in Treating Advanced Lung Cancer in Never Smokers
“Findings from a primary analysis of the phase 2 Harmonic trial (NCT05456256) of the investigational new drug candidate and disulfide small molecule LP-300 (Tavocept, BNP7787, DImesna) with carboplatin and pemetrexed for the treatment of non–small cell lung cancer (NSCLC) in never smokers showed positive results, including a clinical benefit rate (CBR) of 86% and an objective response rate (ORR) of 43%.”
Metastatic NSCLC Survival Rates in the Immunotherapy Era
“The survival rates of patients with advanced non–small cell lung cancer (NSCLC) have improved since the introduction of the first immunotherapeutic in this population in the United States in 2015, according to a recent study published by Wang et al in Cancer. NSCLC accounts for up to 90% of all lung cancer cases and is the leading cause of cancer-related mortality among male and female patients in the United States.”
Metformin in Chemoprevention of Lung Cancer: A Retrospective Population-Based Cohort Study in Lithuania
“Conclusions: This study shows that metformin may have a dose-dependent chemopreventive effect against lung cancer in T2DM, while the impact of pioglitazone remains unclear and requires further investigation.”
Stepped Care Model for Lung Cancer May Maintain QOL With Fewer Visits
“The mean number of palliative care visits was nearly halved for stepped-palliative care vs early palliative care in patients with advanced lung cancer.”
Biomarkers for Lung Cancer Found Using Circadian-Rhythm Data
“The researchers write, “This model demonstrates a dependable capacity to forecast the outcome of the disease, which can further guide the relevant mechanism of lung adenocarcinoma and combine behavioral therapy with treatment to optimize treatment decision-making.””
Can Adjunctive AI Facilitate Earlier Lung Cancer Detection on Pre-Op CT Scans?
“New research shows the use of adjunctive AI resulted in a 12 percent higher sensitivity rate for lung nodule detection in comparison to radiologists without AI.”
Video:
Panel Discusses How to Talk to Patients About Starting Lung Cancer Treatment
“A roundtable discussion, moderated by Millie Das, MD, covered challenges, advances, and future directions for the diagnosis, treatment, and management of non-small cell lung cancer (NSCLC), as well as critical clinical trial data and updates from the 2024 American Society of Clinical Oncology Annual Meeting. Dr. Das was joined by Ticiana Leal, MD, Martin Dietrich, MD, PhD, and Kent Shih, MD. In the second segment of the roundtable series, the panel discusses how to talk to patients about starting treatment for NSCLC, what to do while awaiting next-generation sequencing (NGS) testing results, and how to help patients navigate treatment options and quality-of-life considerations.”
